Physiological Roles of Amyloid-?? and Implications for its Removal in Alzheimer???s Disease
- 1 January 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs & Aging
- Vol. 21 (10), 621-630
- https://doi.org/10.2165/00002512-200421100-00001
Abstract
The underlying pathological cause of Alzheimer's disease has been postulated to be an excess of amyloid-beta (Abeta) which aggregates into toxic fibrillar deposits within the extracellular space of the brain, thereby disrupting neuronal and synaptic function and eventually leading to neuronal degeneration and dementia. As a result, therapeutic strategies have been developed that are designed to remove Abeta from the brain. Caution needs to be exercised concerning such strategies because, in addition to its presence in neuritic plaques, Abeta has a widespread distribution through the brain and body, even in cognitively normal individuals. Evidence indicates that instead of being a toxic peptide, soluble Abeta serves a variety of physiological functions, including modulation of synaptic function, facilitation of neuronal growth and survival, protection against oxidative stress, and surveillance against neuroactive compounds, toxins and pathogens. These physiological functions must be taken into account when strategies are developed to reduce Abeta load in Alzheimer's disease. Ideally, such strategies should target forms of Abeta that are not bioavailable, such as fibrillar Abeta, or forms that are regarded to be overexpressed in Alzheimer's disease (such as oligomers) while leaving normal soluble Abeta1-40 and Abeta1-42 intact. At present none of the available therapeutic strategies appears to have such selectivity. Until these technical limitations and the uncertainties regarding the effect of depletion of Abeta from the brain are resolved, it would not be prudent to begin further clinical trials.Keywords
This publication has 92 references indexed in Scilit:
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Alzheimer vaccine: amyloid‐β on trialBioEssays, 2003
- Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer’s diseaseNeurobiology of Aging, 2002
- Potential neurotoxic inflammatory responses to Aβ vaccination in humansJournal of Neural Transmission, 2002
- APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout MiceNeuron, 2001
- APP is required during an early phase of memory formationEuropean Journal of Neuroscience, 2000
- Glutamine synthetase, hemoglobin α-chain, and macrophage migration inhibitory factor binding to amyloid β-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer’s disease brain by immunoprecipitationBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Amyloid β-peptide induces apoptosis-related events in synapses and dendritesBrain Research, 1998
- Aluminum Promotes the Aggregation of Alzheimer′s Amyloid β-Protein in VitroBiochemical and Biophysical Research Communications, 1994